44 completed, 15 unknown, 14 recruiting, 8 terminated. 98 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 98 | Completed 44, Unknown 15, Recruiting 14, Terminated 8, Not yet recruiting 7, Active not recruiting 5, Withdrawn 5 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting. - Multiple Myeloma in Relapse | Phase 4 | Not yet recruiting | Odense University Hospital | 50 | 2026-11-01 | 2026-10-21 |
| A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments Elranatamab - Relapsed/Refractory Multiple Myeloma, Multiple Myeloma | Phase 4 | Not yet recruiting | Pfizer | 75 | 2026-10-22 | 2026-10-19 |
| The Safety of Simplified Tranexamic Acid Regimen Tranexamic Acid (TXA) - Trauma Coagulopathy, Hemorrhage | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 60 | 2026-10-01 | 2026-10-09 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| Isa-VRD in TIE HRMM Isatuximab, bortezomib, lenalidomide, dexamethason, Bortezomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 117 | 2026-01-30 | 2026-01-13 |
| Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L - Multiple Myeloma Refractory, Relapsed Multiple Myeloma | Phase 4 | Recruiting | CHU de Quebec-Universite Laval | 80 | 2026-01-05 | 2026-07-22 |
| A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia Zanubrutinib - Waldenström's Macroglobulinemia | Phase 4 | Active not recruiting | BeiGene | 16 | 2025-10-17 | 2026-08-10 |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery fresh frozen plasma, prothrombin complex concentrate - Liver Diseases | Phase 4 | Not yet recruiting | Konkuk University Medical Center | 92 | 2025-09-01 | 2025-07-20 |
| Bioequivalence Studies of Dasatinib 100 Mg Dasatinib 100 MG - Myeloma Multiple | Phase 4 | Not yet recruiting | Centro de Atencion e Investigacion Medica | 46 | 2025-09-01 | 2025-02-12 |
| Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone - Peripheral Neuropathy, Multiple Myeloma, Neoplasms | Phase 4 | Recruiting | Tanta University | 44 | 2025-08-30 | 2025-11-04 |
| A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma Teclistamab - Multiple Myeloma | Phase 4 | Active not recruiting | Johnson & Johnson Private Limited | 75 | 2025-05-22 | 2026-09-25 |
| Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC - IgA Nephropathy, Renal Insufficiency, Chronic | Phase 4 | Recruiting | Christian Medical College, Vellore, India | 585 | 2025-02-15 | 2025-07-14 |
| Plan Development for Giving Teclistamab in the Outpatient Setting Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer | Phase 4 | Recruiting | University Health Network, Toronto | 15 | 2024-11-19 | 2025-12-10 |
| SWIFT - SWIss Factor XIII Trial in PPH Fibrogammin - Postpartum Hemorrhage, Coagulation Disorder | Phase 4 | Recruiting | Christian Haslinger | 988 | 2024-07-09 | 2026-04-27 |
| Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection Carfilzomib, Daratumumab, Lenalidomide - Newly Diagnosed, High Risk | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 59 | 2024-06-12 | 2025-06-12 |
| TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study Tranexamic acid, No Tranexamic acid - Venous Thromboembolism, Venous Thromboses | Phase 4 | Unknown | University Health Network, Toronto | 20 | 2024-06-01 | 2024-06-12 |
| A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation Pentaisomaltose - Malignant Lymphoma, Multiple Myeloma | Phase 4 | Unknown | Pharmacosmos A/S | 150 | 2024-04-30 | 2024-04-03 |
Showing 20 of 98. Sign in to see all of them.
Multiple Myeloma (54) · Waldenstrom Macroglobulinemia (8) · Hemorrhage (5) · Wounds and Injuries (5) · Venous Thromboembolism (4) · Ehlers-Danlos Syndrome (3) · Hemophilia A (3) · Lymphoma (3) · Neoplasms (3) · Neoplasms, Plasma Cell (3) · Pain (3) · Postpartum Hemorrhage (3) · Recurrence (3) · Afibrinogenemia (2)
Hemic and Lymphatic Diseases (98) · Hemorrhagic Disorders (98) · Vascular Diseases (98) · Cardiovascular Diseases (97) · Hematologic Diseases (96) · Immune System Diseases (62) · Blood Protein Disorders (60) · Immunoproliferative Disorders (60) · Lymphoproliferative Disorders (60) · Neoplasms by Histologic Type (60) · Paraproteinemias (60) · Neoplasms (57) · Neoplasms, Plasma Cell (57) · Pathological Conditions, Signs and Symptoms (23)
Dexamethasone (11) · Bortezomib (10) · Lenalidomide (10) · Zoledronic Acid (8) · Fibrinogen (5) · Melphalan (4) · Thalidomide (4) · daratumumab (4) · ixazomib (4) · Cyclophosphamide (3) · Prednisone (3) · Sodium Chloride (3) · tocilizumab (3) · Calcium Dobesilate (2) · Doxorubicin (2)
Peking Union Medical College Hospital (4) · University Health Network, Toronto (4) · Institute of Hematology & Blood Diseases Hospital, China (3) · Novartis Pharmaceuticals (3) · Pfizer (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · The First Affiliated Hospital of Soochow University (3) · Janssen Research & Development, LLC (2) · Johnson & Johnson Private Limited (2) · Novartis (2) · PETHEMA Foundation (2) · Takeda (2) · Amgen (1) · Amsterdam UMC, location VUmc (1) · Anne Louise Tølbøll Sørensen (1)
United States (25) · China (23) · Canada (7) · Spain (7) · France (4) · India (4) · Denmark (3) · Italy (3) · Taiwan (3) · Australia (2) · Brazil (2) · Egypt (2) · Japan (2) · Netherlands (2) · United Kingdom (2)
Shuhua Yi, Doc (3) · Junling Zhuang, MD (2) · Adam R Binder, MD (1) · Alastair Nimmo, MBChB (1) · Anatoly Uss, MD/PhD (1) · Ann Silk, MD (1) · Ashraf M Alaa, BSc of clinical pharmacy (1) · Barry R. Meisenberg, MD (1)
PMID 19246088, PMID 20825986, PMID 21626222, PMID 21912321, PMID 22443312, PMID 22914710, PMID 23446769, PMID 23979267, PMID 26069291, PMID 26644410, PMID 26945358, PMID 28492441, PMID 31777949, PMID 32176833, PMID 32418789, PMID 33042916, PMID 34479938, PMID 34582035, PMID 34755760, PMID 35305111, PMID 36853224, PMID 37236666, PMID 37280083, PMID 37807952, PMID 38079089, PMID 38116642, PMID 38205507, PMID 40345697, PMID 40396505, PMID 40982282, PMID 41062134, PMID 41472522, PMID 41775498, PMID 42243996
2023 (2), 2005 (1), 2014 (1), P30CA138292 (1)